128 related articles for article (PubMed ID: 32289400)
1. Response rates of cutaneous melanoma metastases to diphencyprone: A meta-analysis.
Lôbo MM; Calsavara VF; Ricci BV; Lopes Pinto CA; Bertolli E; Duprat Neto JP
J Am Acad Dermatol; 2020 Dec; 83(6):1812-1813. PubMed ID: 32289400
[No Abstract] [Full Text] [Related]
2. Topical diphencyprone immunotherapy for a large primary melanoma on an elderly leg.
Damian DL; Thompson JF
Am J Clin Dermatol; 2011 Dec; 12(6):403-4. PubMed ID: 21967115
[No Abstract] [Full Text] [Related]
3. Topical diphencyprone immunotherapy for cutaneous metastatic melanoma.
Damian DL; Shannon KF; Saw RP; Thompson JF
Australas J Dermatol; 2009 Nov; 50(4):266-71. PubMed ID: 19916970
[TBL] [Abstract][Full Text] [Related]
4. Diphencyprone as a therapeutic option in cutaneous metastasis of melanoma. A single-institution experience.
Gibbons IL; Sonagli M; Bertolli E; Macedo MP; Pinto CAL; Duprat Neto JP
An Bras Dermatol; 2018 Mar; 93(2):299-301. PubMed ID: 29723355
[TBL] [Abstract][Full Text] [Related]
5. TH17 is involved in the remarkable regression of metastatic malignant melanoma to topical diphencyprone.
Martiniuk F; Damian DL; Thompson JF; Scolyer RA; Tchou-Wong KM; Levis WR
J Drugs Dermatol; 2010 Nov; 9(11):1368-72. PubMed ID: 21061759
[TBL] [Abstract][Full Text] [Related]
6. Treatment of extensive cutaneous metastatic melanoma with topical diphencyprone.
Damian DL; Thompson JF
J Am Acad Dermatol; 2007 May; 56(5):869-71. PubMed ID: 17276544
[TBL] [Abstract][Full Text] [Related]
7. Topical diphencyprone for the treatment of locoregional intralymphatic melanoma metastases of the skin; the 5-year Norwich experience.
Moncrieff M; Fadhil M; Garioch J
Br J Dermatol; 2016 May; 174(5):1141-2. PubMed ID: 26598951
[No Abstract] [Full Text] [Related]
8. Regression of cutaneous metastatic malignant melanoma with topical diphencyprone and oral cimetidine.
Harland CC; Saihan EM
Lancet; 1989 Aug; 2(8660):445. PubMed ID: 2569622
[No Abstract] [Full Text] [Related]
9. Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma.
Damian DL; Saw RP; Thompson JF
J Surg Oncol; 2014 Mar; 109(4):308-13. PubMed ID: 24522938
[TBL] [Abstract][Full Text] [Related]
10. Responses to Topical Diphenylcyclopropenone as an Adjunct Treatment for In-Transit Melanoma: A Tertiary Referral Center Experience.
Veverka KK; Jakub JW; Baum CL
Dermatol Surg; 2018 Dec; 44(12):1501-1508. PubMed ID: 29985863
[TBL] [Abstract][Full Text] [Related]
11. Congenital malignant melanoma and cutaneous metastases treated with diphencyprone.
Fawcett JM; Newell EL; Kennedy CT
Clin Exp Dermatol; 2016 Mar; 41(2):212-3. PubMed ID: 26053880
[No Abstract] [Full Text] [Related]
12. Dramatic regression of cutaneous, nodal, and visceral melanoma metastases.
Damian DL; Saw RPM
J Am Acad Dermatol; 2011 Sep; 65(3):665-666. PubMed ID: 21839330
[No Abstract] [Full Text] [Related]
13. Topical immunotherapy with diphenylcyclopropenone in combination with DTIC and radiation for cutaneous metastases of melanoma.
Trefzer U; Sterry W
Dermatology; 2005; 211(4):370-1. PubMed ID: 16286751
[No Abstract] [Full Text] [Related]
14. Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment.
Gulati N; Carvajal RD; Postow MA; Wolchok JD; Krueger JG
Exp Dermatol; 2016 Jul; 25(7):553-4. PubMed ID: 27061281
[No Abstract] [Full Text] [Related]
15. Meyerson's phenomenon in a patient affected by high-risk melanoma under treatment with interferon-α.
Zonta E; Chiarion V; Zarian H; Peserico A; Alaibac M
Melanoma Res; 2012 Jun; 22(3):284-5. PubMed ID: 22543678
[No Abstract] [Full Text] [Related]
16. Sequencing in management of in-transit melanoma metastasis: Diphencyprone versus isolate limb infusion.
Lo MC; Garioch J; Moncrieff MD
J Plast Reconstr Aesthet Surg; 2020 Jul; 73(7):1263-1267. PubMed ID: 32245735
[TBL] [Abstract][Full Text] [Related]
17. Vemurafenib-induced DRESS/DIHS resulting in spontaneous melanoma regression: an immunological reaction shedding new light on melanoma treatment?
Olteanu C; Scope A; Steinberg-Silman Y; Ziv M; Shear NH; Dodiuk-Gad RP; Markel G
Int J Dermatol; 2020 May; 59(5):e139-e141. PubMed ID: 32212333
[No Abstract] [Full Text] [Related]
18. Subacute cutaneous lupus erythematosus with melanocyte elimination induced by pembrolizumab.
Ogawa-Momohara M; Muro Y; Goto K; Obuse C; Satoh M; Kono M; Akiyama M
J Dermatol; 2020 Jun; 47(6):e217-e219. PubMed ID: 32173880
[No Abstract] [Full Text] [Related]
19. Efficacy of topical diphencyprone for melanoma in-transit metastases: a systematic review and meta-analysis.
Pham JP; Dwyer L; Phan K; Menzies AM; Frew JW
Melanoma Res; 2023 Oct; 33(5):434-436. PubMed ID: 37650727
[No Abstract] [Full Text] [Related]
20. Topical immunotherapy with diphencyprone (DPCP) for in-transit and unresectable cutaneous melanoma lesions: an inaugural Canadian series.
Yeung C; Petrella TM; Wright FC; Abadir W; Look Hong NJ
Expert Rev Clin Immunol; 2017 Apr; 13(4):383-388. PubMed ID: 28121191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]